Core Laboratories CLB Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$753K-1,191% | $5.13M-31.3% | $14.52M+21.0% | $10.67M+16.1% | $69K-98.0% | ||
| $3.76M+1.3% | $3.67M+0.1% | $3.59M-2.2% | $3.67M-2.7% | $3.72M-3.3% | ||
| $5.03M+21.0% | $1.11M— | $1.33M— | $538K— | $4.16M-13.7% | ||
| $3.72M+105% | -$5.99M-948% | $1.41M+260% | $1.35M-62.5% | $1.82M+164% | ||
| $180K+429% | —— | —— | —— | $34K-96.9% | ||
| $241K-63.9% | —— | $549K+10.9% | $935K— | $668K— | ||
| -$5.01M-176% | $4.34M— | —— | —— | $6.61M+5.0% | ||
| $3.46M+1,171% | -$3.91M+6.2% | -$723K+81.4% | $1.72M+647% | $272K+127% | ||
| $2.85M-4.2% | —— | —— | $3.68M+0.2% | $2.97M+639% | ||
| -$845K-237% | —— | -$2.48M— | -$1.5M-123% | $617K+125% | ||
| $1.55M+212% | $378K-71.3% | $0-100% | $2.21M+12.7% | -$1.39M-169% | ||
| -$1.93M-83.5% | -$6.86M— | $1.21M-19.3% | $1.64M+1,477% | -$1.05M-1,250% | ||
| $730K+184% | —— | -$286K+46.8% | —— | -$872K-329% | ||
| -$844K-292% | -$1.71M-180% | -$1.86M-209% | -$658K-276% | $440K+18.6% | ||
| $47K+4.4% | —— | —— | —— | $45K+645% | ||
| $3.97M-40.5% | $7.95M-61.5% | $8.5M-35.1% | $13.92M-18.8% | $6.66M+20.4% | ||
| $3.45M+23.8% | $2.94M-9.2% | $2.01M-26.5% | $3.47M+21.2% | $2.79M-8.7% | ||
| $1.49M+21.2% | $668K-16.7% | $152K+14.3% | $966K+364% | $1.23M+107% | ||
| -$3.39M-539% | -$3.75M-5.4% | $2.39M+587% | -$1.64M-139% | $772K+147% | ||
| $460K-1.9% | $466K-0.6% | $465K-0.9% | $469K-0.2% | $469K+0.2% | ||
| $4M+97.7% | $2.66M-45.8% | $5.01M+2,456% | $2.74M+1,591% | $2.02M+4,495% | ||
| $66M+408% | $12M+100% | $11M-31.3% | $12M+50.0% | $13M-7.1% | ||
| $62M+313% | $16M-20.0% | $20M-16.7% | $12M-42.9% | $15M-11.8% | ||
| $0-100% | $0-100% | -$274K— | $10K+153% | $9K— | ||
| -$457K+89.8% | -$7.12M+63.2% | -$16.45M-86.4% | -$3.2M+76.6% | -$4.48M-9.9% | ||
| $117K-96.0% | —— | —— | $9.08M+226% | $2.95M+1,525% | ||
| $2.88M+27.2% | $1.63M-23.0% | $2.49M-15.4% | $1.81M-28.2% | $2.26M-31.2% | ||
| $2.97M+193% | $9.2M+61.7% | $4.66M-18.0% | $3.86M+8.4% | $1.02M-61.7% | ||
| $180K+429% | —— | —— | —— | $34K-96.9% | ||
| $3.72M+105% | -$5.99M-948% | $1.41M+260% | $1.35M-62.5% | $1.82M+164% | ||
| -$513K+34.1% | $86K— | $1.02M+1.4% | $1.61M+30.2% | -$779K-182% | ||
| $7K+333% | -$379K-551% | $242K-52.6% | $112K+177% | -$3K+98.1% | ||
| $1.55M+212% | $378K-71.3% | $0-100% | $2.21M+12.7% | -$1.39M-169% | ||
| $168K-73.9% | $0-100% | $809K+56.8% | $977K— | $643K-1.1% | ||
| —— | $854K+184% | $854K+184% | $854K+184% | $854K+184% | ||
| $730K+184% | —— | -$286K+46.8% | —— | -$872K-329% | ||
| $241K-63.9% | —— | $549K+10.9% | $935K— | $668K— | ||
| $1.44M+81.7% | $708K-37.9% | $1.02M— | $854K— | $794K— | ||
| -$9K— | $148K+840% | $2K+167% | $0— | $0-100% | ||
| $0-100% | $0— | $5.27M+151% | $1.56M— | $3.12M— | ||
| $1.49M+21.2% | $668K-16.7% | $152K+14.3% | $966K+364% | $1.23M+107% | ||
| $0-100% | $0-100% | -$274K— | $10K+153% | $9K— | ||
| —— | $1.02M— | $1.02M— | $1.02M— | $1.02M— | ||
| $1.48M-25.5% | $445K+463% | $187K-19.7% | —— | $1.99M+65.8% | ||
| -$844K-292% | -$1.71M-180% | -$1.86M-209% | -$658K-276% | $440K+18.6% | ||
| —— | $765.25K— | $765.25K— | $765.25K— | $765.25K— | ||
| $517K-86.7% | $5M-71.2% | $6.5M-37.3% | $10.45M-26.8% | $3.88M+56.4% | ||
| $517K-86.7% | $5M-71.2% | $6.5M-37.3% | $10.45M-26.8% | $3.88M+56.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Core Laboratories generate?
- Core Laboratories (CLB) generated $34.3M in operating cash flow over the trailing twelve months.
- What is Core Laboratories's free cash flow?
- After $11.9M of capital expenditures, Core Laboratories's free cash flow was $22.5M over the trailing twelve months, down 51.1% year over year.
- Where does Core Laboratories's cash flow data come from?
- Every line is extracted from Core Laboratories's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
